Phase 1/2 Trial Testing Combo of Bria-IMT and Immune Checkpoint Inhibitors Begins Dosing Breast Cancer Patients

Phase 1/2 Trial Testing Combo of Bria-IMT and Immune Checkpoint Inhibitors Begins Dosing Breast Cancer Patients
BriaCell Therapeutics has started patient dosing in a Phase 1/2a clinical trial testing its immunotherapy candidate Bria-IMT — used in combination with the immune checkpoint inhibitors Keytruda (pembrolizumab) or Yervoy (ipilimumab) — in advanced breast cancer patients. Still recruiting participants, the study (NCT03328026) is expected to enroll approximately 40 patients who have failed to respond to prior lines of therapy at five clinical sites across the United States. Patients whose cancers express the PD-L1 or PD-L2 proteins will receive the Bria-IMT vaccine in combination with the PD-1 inhibitor Keytruda, developed by Merck (known as MSD outside the U.S. and Canada), while those whose cancers are negative for these proteins will receive Bristol-Myers Squibb's anti-CTLA4 antibody Yervoy. The combination treatment will be given every three weeks. “We believe that combination of Bria-IMT with immune checkpoint inhibitors should create even more potent anti-cancer immune responses, leading to our strategy of combination studies of Bria-IMT with Keytruda or Yervoy,” Bill Williams, MD, PhD, president and CEO of BriaCell, said in a press release. Bria-IMT, formerly known as BriaVax or SV-BR-1-GM, is a vaccine that consi
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.